Biblio Discovery — Demo Discovery Service

23 results for "Alexander Meisel"

Showing 1–20 · 0.47 seconds · RSS

  1. Journal Article

    Critical Review of EGFR-Mutated NSCLC What We Do and Do Not Know

    Alexander Meisel

    healthbook TIMES. Oncology Hematology, Vol. 1 No. 3 · 2020 · English · DOAJ Scopus

    The recent advances in EGFR M+ NSCLC and the availability of different treatment options, including treatment novelities such as osimertinib and afatinib, are summarized in this review.

    Also available at: DOAJ

  2. Journal Article

    Therapy Management of Metastatic Prostate Carcinoma in General Practice

    Alexander Meisel

    healthbook TIMES. Oncology Hematology, Vol. 1 No. 1 · 2019 · English · DOAJ Scopus

    In general, advanced prostate cancer is initially treated with androgen deprivation therapy (ADT). Despite high response rates to this treatment, the response is not durable and most of the patients eventually develop metastatic castration-resistant prostate cancer (mCRPC). The treatment strategies…

    Also available at: DOAJ

  3. Journal Article

    The Microbiome and Cancer: A Dangerous Liaison

    Alexander Meisel

    healthbook TIMES. Oncology Hematology, Vol. 2 No. 8 · 2021 · English · DOAJ Scopus

    Variations in the human gut microbiome might reflect an individual’s lifestyle and influence their blood levels of disease biomarkers. Understanding the connections between gut microbes and host phenotypes is crucial for determining health and disease. The gastrointestinal tract has the largest…

    Also available at: DOAJ

  4. Journal Article

    Avenues to Precision Oncology

    Alexander Meisel

    healthbook TIMES. Oncology Hematology, Vol. 1 No. 3 · 2020 · English · DOAJ Scopus

    Until recently, the clinical management of cancer heavily relied on anatomical and histopathological criteria, with ad hoc guidelines directing the therapeutic choices in specific indications. In the last years, the development and therapeutic implementation of novel anticancer therapies…

    Also available at: DOAJ

  5. Journal Article

    Genomic Testing for Advanced Prostate Cancer: Ready for Prime Time?

    Alexander Meisel

    healthbook TIMES. Oncology Hematology, Vol. 2 No. 2 · 2019 · English · DOAJ Scopus

    In this review, the potential benefits of genomic testing for advanced prostate cancer are reported.

    Also available at: DOAJ

  6. Journal Article

    mRNA Vaccines Against Infectious Diseases and Cancer

    Alexander Meisel; Steve Pascolo

    healthbook TIMES. Oncology Hematology, Vol. 9 No. 3 · 2021 · English · DOAJ Scopus

    Synthetic mRNA acts as a template for synthesizing proteins, protein fragments, or peptides and now has many pharmaceutical applications.^1,2^ Coronavirus disease 2019 (COVID-19) due to infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), a novel zoonotic RNA virus, has…

  7. Journal Article

    PSMA-Directed Theragnostics: Transforming Prostate Cancer Landscape

    Alex Friedlaender; Olivier Rager; Alexander Meisel

    healthbook TIMES. Oncology Hematology, Vol. 15 No. 1 · 2023 · English · DOAJ Scopus

    Early diagnosis and the detection of distant metastases and recurrences in patients with prostate cancer (PCa) have been notably improved in recent decades through advances in imaging techniques. More recently, positron emission tomography (PET) hybrid imaging (PET/computed tomography \[CT] and…

  8. Journal Article Full text

    The G Protein-Coupled Estrogen Receptor (GPER) Is Expressed in Two Different Subcellular Localizations Reflecting Distinct Tumor Properties in Breast Cancer

    Eleftherios P. Samartzis; Aurelia Noske; Alexander Meisel et al.

    PLoS ONE, Vol. 9 No. 1 · 2014 · English · PLOS Scopus

    Introduction: The G protein-coupled estrogen receptor (GPER) is a novel estrogen receptor that mediates proliferative effects induced by estrogen but also by tamoxifen. The aim of our study was to analyze the frequency of GPER in a large collective of primary invasive breast carcinomas, with…

    Also available at: DOAJ

  9. Journal Article

    Tafasitamab and Lenalidomide as Second-Line Treatment in an Elderly Patient with a Primary Refractory Double-Hit Diffuse Large B-Cell Lymphoma

    Alexander Meisel; Ziad Kassem; Daniel Turek et al.

    healthbook TIMES. Oncology Hematology, Vol. 23 No. 1 · 2025 · English · DOAJ Scopus

    The phase II L-MIND study demonstrated that treatment with tafasitamab in combination with lenalidomide yielded high complete response rates in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients with primary refractory DLBCL relapsing within three months of…

  10. Journal Article

    Temsirolimus Is Highly Effective as Third-Line Treatment in Chromophobe Renal Cell Cancer

    Dimitrios Zardavas; Alexander Meisel; Panagiotis Samaras et al.

    Case Reports in Oncology, Vol. 4 No. 1 · 2011 · English · DOAJ Scopus

    We report unexpectedly high efficacy of temsirolimus as third-line treatment in a patient with metastatic chromophobe renal cell carcinoma. After failure of two sequentially administered tyrosine kinase inhibitors, treatment with temsirolimus resulted in a prolonged partial remission of 14 months…

  11. Journal Article

    Metastatic Pancreatic Cancer: Current Treatment Options for Swiss Patients

    Sara De Dosso; Alexander R. Siebenhüner; Thomas Winder et al.

    healthbook TIMES. Oncology Hematology, Vol. 2 No. 8 · 2021 · English · DOAJ Scopus

    Despite oncological advances over the past years, survival outcomes for patients with pancreatic ductal adenocarcinoma (PDAC) remain poor. For most PDAC patients, the disease is often asymptomatic at early phases and is therefore typically diagnosed at the advanced or metastatic stage. As a result…

    Also available at: DOAJ